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eprivation, school and work disruptions, rib fractures, and
neumonia.
Adolescents and adults not only experience substantial
orbidity and complications from pertussis, they play an
mportant role in transmission of Bordetella pertussis to
hildren. Multiple studies have documented that parents and
ther family members are the main source of pertussis infec-
ion in infants. Of particular concern are very young infants,
ho are at greatest risk for hospitalization and mortality
rom pertussis, and who are either incompletely vaccinated
r unvaccinated.
To address these concerns, adolescent/adult-formulation
etanus-diphtheria-acellular pertussis (Tdap) vaccines,
ometimes combined with injectable polio vaccine, have
een developed. These Tdap vaccines have been shown
n clinical trials to be safe and at least as immunogenic
gainst pertussis as their analogous pediatric vaccines. In
anada and the US, Tdap vaccination is recommended for
ll adolescents and adults < 64 years of age. Emphasis is
laced on vaccinating young adolescents and on vaccinating
dults (eg, new parents, child-care workers, and certain
ealthcare-personnel) who have close contact with infants.
anadian experience suggests that Tdap vaccine usage has
ontributed to further decreases in pertussis. Full control
f this disease, however, may require decennial boosting
ith Tdap vaccine, which is currently under study.
oi:10.1016/j.ijid.2008.05.065
ew Perspectives on Vaccine-preventable Diseases in
dults: Pneumococcal Disease and Herpes Zoster (invited)
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pening Remarks - Adult Immunisation: Some Thoughts
. Hanna
Communicable Disease Control, Tropical Population Health
nit Network, Queensland Health, Cairns, Australia
dult immunisation can be categorised in several ways:-
mmunisation for travel - immunisation for certain occupa-
ions (eg. health-care and child-care workers)- immunisation
or those with certain medical conditions (eg. asplenia), -
mmunisation for the elderly.
Immunisation for the elderly, in particular, is gaining
reater recognition and greater credibility. Ageing pop-
lations, the increasing prevalence of certain medical
onditions in the aged, and a desire to keep the aged in opti-
al health, all have contributed to this recognition of the
eed for vaccines for, and for the delivery of these vaccines
o, the aged.
However, this greater recognition of the need has not
et been matched by greater uptake of vaccines by the
lderly, even in afﬂuent industrialised countries. For exam-
le, uptake of the annual inﬂuenza vaccine in those aged
65 years in the United States increased from 33% to 66% in
he 1990s, but has not increased since. Other countries do
ot even have mechanisms in place to determine the cov-
rage of vaccines in the elderly; in Australia, for example,
lthough inﬂuenza and pneumococcal polysaccharide vac-
ines are provided free to those aged ≥65 years, there is not
et a mechanism to determine uptake of these vaccines.
l
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Perhaps the main reasons for this disconnection between
ntent and outcome are that ‘‘adult immunisation is not yet
n essential element within the culture of adult medicine
or is it a health care priority in the minds of the public’’.
his suggests that increasing demand for adult immunisation
y improving professional and public awareness should be
iven greater priority; indeed this need for greater aware-
ess has been given priority in a recent policy statement on
dult immunisation from the Infectious Diseases Society of
merica.
oi:10.1016/j.ijid.2008.05.066
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. Levin
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aricella (chickenpox) is associated with a viremia that
esults in a life-long association of the varicella-zoster virus
VZV) with neurons in sensory ganglia. VZV remains in a clin-
cally inapparent (latent) form in these neurons because of
he presence of VZV-speciﬁc immune responses that appear
t the time of the childhood varicella infection. However,
hen these responses decline, as occurs with immune sup-
ression, the latent VZV reactivates and causes herpes
oster (HZ). These same protective responses also decline
aturally as part of the aging process. This explains why
Z occurs in approximately one-quarter of all people in
heir lifetime; 20% of cases occur in those who are 50—59
ears old and 60% occur in older people (incidence is 1/100
ersons per year for those ≥60 years). Not only does the
ncidence of HZ increase with aging, but the duration and
everity of this painful disease increases with aging, as
oes its main complication - prolonged pain (post-herpetic
euralgia; PHN). Since HZ is the consequence of declining
ZV-speciﬁc immunity, it was suggested that boosting this
mmunity in older people would prevent HZ and/or lessen
ts severity. A double-blinded, placebo-controlled, trial of a
ive, attenuated, HZ vaccine has proven this hypothesis to
e correct. The HZ vaccine reduced the frequency of HZ (by
0%) and it reduced the pain and suffering (including PHN) by
65%, and as a consequence, is recommended in the United
tates for routine use in people ≥60 years of age. The details
f the clinical trial and potential issues raised by its use will
e discussed.
oi:10.1016/j.ijid.2008.05.067
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erpes Zoster and Post Herpetic Neuralgia (PHN) - The
aiwan Perspective
.C. Yang
Department of Neurology, National Taiwan University, Col-
ege of Medicine, Taipei, Taiwan
he objective of this study is to estimate the incidence of
Z among the Taiwanese population, and investigate the
isease burden of HZ by analyzing the utilization of health
